Journal of Volgograd State Medical UniversityJournal of Volgograd State Medical University1994-94801994-9499Volgograd State Medical University11939510.19163/1994-9480-2020-1(73)-133-136Research ArticleSTUDY OF EFFICIENCY OF 3-OXYPIRIDINE DERIVATIVES IN CORRECTION OF DISORDERS IN THE CONDITIONS OF EXPERIMENTAL PREECLAMPSIAYurakovaA. V.-SkachilovaS. Ya.-DanilenkoL. M-ZatolokinaM. Amarika1212@mail.ruZatolokinaE. S-GureevaA. V.-FSAEI HE «Belgorod State National Research University»SC «All-Union Scientific Center for the Safety of Biologically Active Substances»FSBEI HE «Kursk State Medical University» of Public Health Ministry of the Russian Federation1501202017113313618122022Copyright © 2020, Yurakova A.V., Skachilova S.Y., Danilenko L.M., Zatolokina M.A., Zatolokina E.S., Gureeva A.V.2020The pathogenesis of preeclampsia is polyetiologic and not fully understood. One of the leading theories of pathogenesis is the theory of oxidative stress. Accordingly, the search for new drugs with antioxidant and antihypoxic effects is promising for the prevention and treatment of preeclampsia. Methods. The experiment was performed on 140 female white rats of Wistar strain weighing 250-300 g. The studied substances were administered within 7 days from 14 to 21 days of pregnancy. On the 21st day of pregnancy, functional tests were conducted. Results. Administration of 3-oxypiridine derivates in animals causes the expressed correction of pathological changes in experimental ADMA-like preeclampsia. There was a significant rise in systolic and diastolic blood pressure, respectively, the improvement of microcirculation in the placenta, restoration of endothelium NO-synthesis function, proteinuria reduction. Conclusion. The results of this study prove the future outlook of the use of 3-oxypiridine derivates for correction of functional changes in preeclampsia and substantiate the reasonability of further research in this direction.preeclampsia3-oxypiridinemexidolendothelial dysfunctionratsproteinuriamicrocirculationпреэклампсия3-оксипиридинмексидолэндотелиальная дисфункциякрысыпротеинуриямикроциркуляция[Gureev V.V., Alehin S.A., Pokrovskiy M.V., Dolghikov A.A., Korokin M.V., Gudyrev O.S., Kolesnik I.M. Remote ischemic preconditioning correction in ADMA-like gestosis model // Research Journal of Pharmaceutical, Biological and Chemical Sciences. - 2014. - № 5 (5). -P. 1095-1098.][Danilenko L.M., Skachilova S.Ya., Nadezhdin, S.V., et al. Pharmacological screening of substances with cardioprotective effect in the group of 3-oxypyridine derivatives // Research Results in Pharmacology. - 2018. - Vol. 4, № 2. - P. 125-131.][Danilenko L.M., Pokrovskii M.V. 3-(2,2,2-trimethyl-hydrazinium) propionate: New concept of realization of cardioprotective effect // Res. J. Pharm. Biol. Chem. Sci. - 2014. - № 5. - P. 1419-22.][Danilenko L.M., Parfenov E.A., Pokrovsky M.V., Gumanova N.G., Metelskaya V.A., Bobrakov K.E., et al. The use of metal complexes with antioxidant properties for pharmacological correction of endothelial dysfunction // Kuban. Sci. Med. J. - 2009. - № 5. - P. 20-4.][Korokin M.V., Gudyrev O.S., Gureev V.V. Studies to elucidate the effects of furostanol glycosides from dioscorea deltoidea cell culture in a rat model of endothelial dysfunction // Molecules. - 2020. - № 25 (1). - P. 169.][Pokrovskii M.V., Pokrovskaia T.G., Gureev V.V., et al. Correction of endothelial dysfunction by L-arginine under experimental pre-eclampsia conditions // Eksperimental'Naya i Klinicheskaya Farmakologiya. - № 75 (2). - P. 14-16.][Pokrovskii M.V., Yurakova A.V, Gureev V.V., et al. Integrated evaluation of the endothelioprotective activity of an innovative peptide simulating the alpha-helix of b-erythropoethin in L-NAME-induced nitrogen oxide deficiency at the late gestation period // Journal of Critical Reviews. - 2019. - № 6 (6). - P. 180-184.][Severinova O.V., Lokteva T.I., Gureev V.V., et al. The effect of arginase II selective inhibitors on the functional parameters of experimental animals in ADMA-like preeclampsia // Journal of International Pharmaceutical Research. - 2019. - № 46 (4). - P. 272-275.][Skachilova S.Y., Kesarev O.G., Danilenko L.M., Bystrova N.A., Dolzhikov A.A., Nikolaev S.B. Pharmacological correction of L-NAME-induced oxide deficiency with derivatives of 3-(2,2,2-trimethylhydrazinium) propionate // Res. Result. - 2016. - № 1. - P. 36-41.][Smirnov L.D., et al. Effect of a 3-hydroxypyridine derivative membrane modulator on pharmacological activity of some psychotropic drugs // Bulletin of experimental biology and medicine. - 1985. - Vol. 99 (5). - Р. 537-540.]